No Detail Found!

Combinations of long acting β2 agonists to tiotropium: A randomized, double‑blind, placebo‑controlled, active-drug controlled, parallel design academic clinical trial in moderate COPD male patients

Author(s)
Mohammed Imran Department of Pharmacology, Shaheed Hasan Khan Mewati Government Medical College, Nalhar, Nuh, Mewat, Haryana, India
Sunil Kumar Chhabra Department of Cardiorespiratory Physiology, Vishwanathan Chest Hospital, University of Delhi, Delhi, India
Anita Kotwani Vallabhbhai Patel Chest Institute and Vishwanathan Chest Hospital, University of Delhi, Delhi, India
Abstract
Introduction: The fixed dose combinations used in chronic obstructive pulmonary disease  (COPD) patients need their rationale evaluation. If there is no added benefit; then it amounts economic burden on the society, reduced compliance, and unsuccessful therapy. This study evaluated the effectiveness of three regimens of dry powder inhaled preparations including tiotropium 18  µg once a day; tiotropium 18  µg plus formoterol 12  µg once a day, and tiotropium 18  µg once a day plus formoterol 12  µg twice a day in moderate COPD patients. Materials and Methods: A randomized, double-blind, placebo-controlled, active drug controlled parallel design study was conducted in 42 moderate COPD patients without any other comorbidity. Three (R1, R2, and R3) regimens were evaluated in patients to assess the appropriate evidenceb-ased pharmacotherapy regimen. The forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), Borg's scale of dyspnea, and vital signs (blood pressure and pulse rate) were measured on serial time points for 24 h. Results: The trough FEV1 values of R1, R2, and R3 in liters were 1.836  ±  0.51, 1.886 ± 0.47, and 1.805 ± 0.37, respectively and did not show any statistical difference. No statistical significance was observed in FVC (liters), FEV1% predicted, ?FEV1 (liters), ?FEV1% predicted, ?FVC % predicted, and ? FVC (liters) except in 24 h FVC percentage predicted values where P - value for R3 is in the range between 0.05 and 0.1 over R1. Conclusions: Study shows that tiotropium alone once a day is the evidence based and rationale pharmacotherapy in moderate COPD. There is no advantage or statistical significance of adding long acting ß agonists  (LABA) such as formoterol to tiotropium either for 12 h  (once daily) or 24 h  (twice daily).
Publication Details
Page(s) 19-24
Published Journal: Archives of Pharmacy Practice, Volume: 6, Issue: 2, Year: 2015

Request the full text from PASTIC

Keywords
Forced expiratory volume, in1, long acting, Forced vital capacity
References
Global .2015 .Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2013. Available from: www. com [Last accessed on 15 Jan, : .
.2013 .Chronic obstructive pulmonary disease. Indian J Med Res, 137 : 251-69.
. .. [Last accessed on 2015 Jan, 15 : .
Kim ,Lee SW .2014 .Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis, 18 : 737-43.
Heart National . .‑chart‑book. htm; 2012. [Last accessed on 2015 Jan, 15 : .
.2008 .Screening for chronic obstructive pulmonary disease using spirometr y: U. S. preventive Ser vices task Force recommendation statement. Ann Intern Med, 148 : 529-34.
.2005 .Standardisation of lung function testing interpretative strategies for lung function tests. Eur Respir J, 26 : 948-68.
Balasubramanian ,Radhika N .2014 .The crave of fixed dose combination in Indian market. 2015 Jan, 15 : 106-10.
Comfort Christopher . .The COPD drug market will become more fractured as several new agents reach the market and erode the dominance of the current market leaders. [Last accessed on 2015 Jan, 15 : .
.2013 .Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res, 14 : 49.
Cazzola ,di Marco .2004 .The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med, 98 : 1214-21.
Vogelmeier ,Formoterol .2008 .and combination therapy with tiotropium in patients with COPD: A 6‑month study. Respir Med, 102 : 1511-20.
Z ,SA .2010 .A preliminary randomized open labeled comparative analysis of efficacy and safety of inhaled Tiotropium and Tiotropium plus Formoterol in COPD. php?volume=12 and issueno=1 [Last accessed on 2015 Jan, 15 : 27-30.
.2011 .Triple inhalers for obstructive airways disease: Will they be useful?. Expert Rev Respir Med, 5 : 297-300.
Celik ,Beder .1999 .Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo‑controlled comparison of onset and duration of action. Respiration, 66 : 434-9.
Casaburi A .2002 .A long‑term evaluation of once‑daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19 : 217-24.
Thorn ,Swensen A,Holguin A .2008 .Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J, 32 : 962-9.
Borg .1982 .Psychological basis of perceived exertion. Med Sci Sports Exer, 14 : 377-87.
Postma DS,De Vries DS .1985 .Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci (Lond), 69 : 251-8.
N ,Green N,Y N .2013 .Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study. Eur Respir J, 42 : 1484-94.
Wedzicha JA,Decramer M,Ficker JH,Niewoehner DE,SandstroANm T,Taylor AF .2013 .Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium  (SPARK): A  randomised, double‑blind, parallel‑group study. Lancet Respir Med, 1 : 199-209.
0

Citations

0

Downloads

8

Views